These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20675856)

  • 1. Successful treatment with infliximab of a patient with tumor necrosis factor-associated periodic syndrome (TRAPS) who failed to respond to etanercept.
    Krelenbaum M; Chaiton A
    J Rheumatol; 2010 Aug; 37(8):1780-2. PubMed ID: 20675856
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS).
    Siebert S; Amos N; Lawson TM
    Rheumatology (Oxford); 2008 Feb; 47(2):228-9. PubMed ID: 18056150
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment.
    Stojanov S; Dejaco C; Lohse P; Huss K; Duftner C; Belohradsky BH; Herold M; Schirmer M
    Ann Rheum Dis; 2008 Sep; 67(9):1292-8. PubMed ID: 18180277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed?
    Yazici Y; Erkan D
    Ann Rheum Dis; 2004 May; 63(5):607-8; author reply 608. PubMed ID: 15082503
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome.
    Drewe E; Huggins ML; Morgan AG; Cassidy MJ; Powell RJ
    Rheumatology (Oxford); 2004 Nov; 43(11):1405-8. PubMed ID: 15316120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS).
    Jacobelli S; André M; Alexandra JF; Dodé C; Papo T
    Rheumatology (Oxford); 2007 Jul; 46(7):1211-2. PubMed ID: 16935919
    [No Abstract]   [Full Text] [Related]  

  • 7. Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A.
    Nowlan ML; Drewe E; Bulsara H; Esposito N; Robins RA; Tighe PJ; Powell RJ; Todd I
    Rheumatology (Oxford); 2006 Jan; 45(1):31-7. PubMed ID: 16287931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome.
    Nedjai B; Hitman GA; Quillinan N; Coughlan RJ; Church L; McDermott MF; Turner MD
    Arthritis Rheum; 2009 Feb; 60(2):619-25. PubMed ID: 19180495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
    Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
    Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis.
    Kallinich T; Briese S; Roesler J; Rudolph B; Sarioglu N; Blankenstein O; Keitzer R; Querfeld U; Haffner D
    J Rheumatol; 2004 Dec; 31(12):2519-22. PubMed ID: 15570662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective co-administration of infliximab and etanercept following the failure of sequential anti-TNF agents in a patient with HLA-B27-associated arthropathy.
    Sheehy C; Murphy E; Barry M
    Rheumatology (Oxford); 2006 Oct; 45(10):1314-5. PubMed ID: 16837474
    [No Abstract]   [Full Text] [Related]  

  • 12. Psoriatic arthritis patients doing better on infliximab than etanercept.
    Smith N; Gadsby K; Deighton C
    Rheumatology (Oxford); 2007 Apr; 46(4):721-2. PubMed ID: 17314216
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumor necrosis factor receptor-associated periodic fever syndrome in a 58-year-old man: caution not to discount TRAPS as a diagnosis in older patients.
    Sinožić D; Toplak N; Milotić I
    J Clin Rheumatol; 2011 Sep; 17(6):325-8. PubMed ID: 21869706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etanercept and infliximab for rheumatoid arthritis.
    Drug Ther Bull; 2001 Jul; 39(7):49-52. PubMed ID: 11471515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients.
    Drewe E; McDermott EM; Powell PT; Isaacs JD; Powell RJ
    Rheumatology (Oxford); 2003 Feb; 42(2):235-9. PubMed ID: 12595616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis.
    Blank N; Max R; Schiller M; Briem S; Lorenz HM
    Rheumatology (Oxford); 2009 Apr; 48(4):440-1. PubMed ID: 19153143
    [No Abstract]   [Full Text] [Related]  

  • 17. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
    Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 19. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
    Buch MH; Seto Y; Bingham SJ; Bejarano V; Bryer D; White J; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.